On May 21, the governing body of the Cancer Prevention and Research Institute of Texas approved 61 grants totaling more than $93 million. The grants support cancer research and prevention projects across the entire spectrum of CPRIT’s mission, including CPRIT Scholar recruitment grants, a wide array of evidence-based prevention programs, and funding for early-stage companies developing promising new treatments for cancer.
The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research.
The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP.
The National Institute for Health Care Management Foundation is now accepting letters of inquiry for the 2025-2026 funding cycle of NIHCM Foundation’s Research Grant program. We will be awarding a total of $500,000 in grants to support innovative, independent, investigator-initiated research that has the potential to inform managed care organizations, policymakers, and related stakeholders to improve the affordability and quality of U.S. health care.
An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient’s blood, developed by Johns Hopkins Kimmel Cancer Center investigators, could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.
Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.
A Johns Hopkins Medicine-led research team has identified a recurrent frameshift mutation, called F722fs, in the MMS22L gene among men of Ashkenazi Jewish ancestry that is associated with a higher risk of prostate cancer and increased sensitivity to a specific anticancer therapy.
A team led by researchers at Baylor College of Medicine has identified flavonoids, natural compounds found in plants, that are toxic to bladder cancer cells cultured in the lab.
Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction.
A widely used antidepressant drug could help the immune system fight cancer, according to a new research study from UCLA.
